BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 30922100)

  • 1. Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity.
    Jha MK; Minhajuddin A; South C; Rush AJ; Trivedi MH
    Am J Psychiatry; 2019 May; 176(5):358-366. PubMed ID: 30922100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials.
    Jha MK; South C; Trivedi J; Minhajuddin A; Rush AJ; Trivedi MH
    Int J Neuropsychopharmacol; 2019 May; 22(5):339-348. PubMed ID: 30958879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.
    Chekroud AM; Gueorguieva R; Krumholz HM; Trivedi MH; Krystal JH; McCarthy G
    JAMA Psychiatry; 2017 Apr; 74(4):370-378. PubMed ID: 28241180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Rajpurkar P; Yang J; Dass N; Vale V; Keller AS; Irvin J; Taylor Z; Basu S; Ng A; Williams LM
    JAMA Netw Open; 2020 Jun; 3(6):e206653. PubMed ID: 32568399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial.
    Friedman ES; Davis LL; Zisook S; Wisniewski SR; Trivedi MH; Fava M; Rush AJ;
    Eur Neuropsychopharmacol; 2012 Mar; 22(3):183-99. PubMed ID: 21920711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
    Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
    J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation.
    De La Garza N; Rush AJ; Killian MO; Grannemann BD; Carmody TJ; Trivedi MH
    Depress Anxiety; 2019 Apr; 36(4):313-320. PubMed ID: 30370613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between irritability and suicidal ideation in three clinical trials of adults with major depressive disorder.
    Jha MK; Minhajuddin A; Chin Fatt C; Kircanski K; Stringaris A; Leibenluft E; Trivedi MH
    Neuropsychopharmacology; 2020 Dec; 45(13):2147-2154. PubMed ID: 32663842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report.
    Fava M; Rush AJ; Wisniewski SR; Nierenberg AA; Alpert JE; McGrath PJ; Thase ME; Warden D; Biggs M; Luther JF; Niederehe G; Ritz L; Trivedi MH
    Am J Psychiatry; 2006 Jul; 163(7):1161-72. PubMed ID: 16816220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychometric Properties of the Concise Associated Symptom Tracking Scale and Validation of Clinical Utility in the EMBARC Study.
    Minhajuddin A; Jha MK; Fatt CC; Trivedi MH
    Psychiatr Res Clin Pract; 2020; 2(1):10-18. PubMed ID: 36101888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial.
    Jha MK; Malchow AL; Grannemann BD; Rush AJ; Trivedi MH
    Neuropsychopharmacology; 2018 Oct; 43(11):2197-2203. PubMed ID: 30135556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Worsening Anxiety, Irritability, Insomnia, or Panic Predicts Poorer Antidepressant Treatment Outcomes: Clinical Utility and Validation of the Concise Associated Symptom Tracking (CAST) Scale.
    Jha MK; Minhajuddin A; South C; Rush AJ; Trivedi MH
    Int J Neuropsychopharmacol; 2018 Apr; 21(4):325-332. PubMed ID: 29182724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
    Bobo WV; Chen H; Trivedi MH; Stewart JW; Nierenberg AA; Fava M; Kurian BT; Warden D; Morris DW; Luther JF; Husain MM; Cook IA; Lesser IM; Kornstein SG; Wisniewski SR; Rush AJ; Shelton RC
    J Affect Disord; 2011 Oct; 133(3):467-76. PubMed ID: 21601287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.
    Noma H; Furukawa TA; Maruo K; Imai H; Shinohara K; Tanaka S; Ikeda K; Yamawaki S; Cipriani A
    J Affect Disord; 2019 May; 250():419-424. PubMed ID: 30878654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.
    Rush AJ; Trivedi MH; Stewart JW; Nierenberg AA; Fava M; Kurian BT; Warden D; Morris DW; Luther JF; Husain MM; Cook IA; Shelton RC; Lesser IM; Kornstein SG; Wisniewski SR
    Am J Psychiatry; 2011 Jul; 168(7):689-701. PubMed ID: 21536692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial of Psilocybin versus Escitalopram for Depression.
    Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
    N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study.
    Rush AJ; South C; Jha MK; Jain SB; Trivedi MH
    J Clin Psychiatry; 2020 Aug; 81(5):. PubMed ID: 32780949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.
    Jha MK; Wakhlu S; Dronamraju N; Minhajuddin A; Greer TL; Trivedi MH
    J Affect Disord; 2018 Jul; 234():34-37. PubMed ID: 29522941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.